Endocrine Metabolic & Immune Disorders-drug Targets

Endocrine Metabolic & Immune Disorders-drug Targets

内分泌代谢和免疫疾病-药物靶点

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Endocrine Metabolic & Immune Disorders-drug Targets》是由Bentham Science Publishers B.V.出版社于2001年创办的英文国际期刊(ISSN: 1871-5303,E-ISSN: 2212-3873),该期刊长期致力于内分泌学与代谢领域的创新研究,主要研究方向为ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY。作为SCI、SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0041...%),以发表内分泌学与代谢领域等方向的原创性研究为核心(研究类文章占比71.01%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在69篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Endocrine Metabolic & Immune Disorders-drug Targets该刊近年未被列入国际预警名单,年发文量约69篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 69 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

期刊分区表(2021年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q4 152 / 198

23.5

学科:IMMUNOLOGY SCIE Q4 149 / 183

18.9

学科:PHARMACOLOGY & PHARMACY SCIE Q3 249 / 356

30.2

学科:ENDOCRINOLOGY & METABOLISM SCIE Q4 152 / 198

23.48

学科:IMMUNOLOGY SCIE Q4 144 / 183

21.58

学科:PHARMACOLOGY & PHARMACY SCIE Q3 266 / 356

25.42

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q3 134 / 186

28.2

学科:IMMUNOLOGY SCIE Q4 144 / 181

20.7

学科:PHARMACOLOGY & PHARMACY SCIE Q3 222 / 354

37.4

学科:ENDOCRINOLOGY & METABOLISM SCIE Q4 149 / 186

20.16

学科:IMMUNOLOGY SCIE Q4 139 / 181

23.48

学科:PHARMACOLOGY & PHARMACY SCIE Q3 265 / 354

25.28

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:4.1 SJR:0.552 SNIP:0.555
学科类别 分区 排名 百分位
大类:Medicine 小类:Endocrinology, Diabetes and Metabolism Q3 129 / 250

48%

大类:Medicine 小类:Immunology and Allergy Q3 136 / 234

42%

期刊发文

  • Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rat

    Author: Ping, Nan; Qin, Na

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303391165250828111133

  • The Emerging Role of tRNA-Derived Small RNAs (tsRNAs) in Radiation-Induced Cardiovascular Patholog

    Author: Chen, Ying; Zhu, Yunjia; Qian, Lingmei; Hu, Qunchao

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303460374260127095032

  • LGI1 Antibody-Associated Encephalitis Complicated with Sjögren's Syndrome and Acute Cerebral Infarction: A Case Report and Literature Revie

    Author: Jiang, Dongxiao; Lian, Yanfen; Zhan, Xia; Wang, Jingjing; Xu, Pengjiao; Bi, Yuhua

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410062250729095927

  • From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravi

    Author: Chen, Zhimin; Kong, Xiaotong; He, Ping; Na, Risu; Wang, Lihua

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303446341260204093655

  • UBE2M Identified by CRISPR Screening as a Key Regulator of Cisplatin-Induced Acute Kidney Injury via the p53 Pathwa

    Author: Yuan, Cheng; Chen, Feng; Gao, Xueyun; Yusufu, Ayinigaer; Lu, Danqin; Wu, Xiaoyan; Ni, Lihua

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410982251112055248

  • EphrinB2 Ameliorates Renal Fibrosis by Inhibiting the TGF-β/Smad3 Signaling Pathway and the Inflammation Respons

    Author: Yuan, Cheng; Zhou, Qiuyuan; Chen, Feng; Gao, Xueyun; Yusufu, Ayinigaer; Wu, Xiaoyan; Ni, Lihua

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303366454250507042518

  • Unlocking New Treatment Horizons for Celiac Disease: PRKCD Revealed as a Promising Target through Mendelian Randomizatio

    Author: Zhou, Jie; Xu, Yixin; Wang, Haitao; Wang, Kun; Chen, Chao

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410531250815124524

  • Evaluation of the Space GlucoseControl System for Managing Stress-Induced Hyperglycemia in ICU Patients: Efficacy and Safety Assessmen

    Author: Liu, Peng-Cheng; Fan, Dan-Dan; Bao, Qun-Ying; Jiang, Xiao-Mei; Lu, Juan

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303346311250415111740